BR0014827A - Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém - Google Patents

Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém

Info

Publication number
BR0014827A
BR0014827A BR0014827-0A BR0014827A BR0014827A BR 0014827 A BR0014827 A BR 0014827A BR 0014827 A BR0014827 A BR 0014827A BR 0014827 A BR0014827 A BR 0014827A
Authority
BR
Brazil
Prior art keywords
preparation
imidazo
pyridin
methyl
amine derivatives
Prior art date
Application number
BR0014827-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Corina Maul
Bernd Sundermann
Hagen-Heinrich Hennies
Johannes Schneider
Mathias Gerlach
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR0014827A publication Critical patent/BR0014827A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR0014827-0A 1999-10-08 2000-10-06 Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém BR0014827A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19948434A DE19948434A1 (de) 1999-10-08 1999-10-08 Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
PCT/EP2000/009791 WO2001027109A2 (de) 1999-10-08 2000-10-06 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridin-3-yl)-amin-derivate

Publications (1)

Publication Number Publication Date
BR0014827A true BR0014827A (pt) 2003-07-08

Family

ID=7924888

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014827-0A BR0014827A (pt) 1999-10-08 2000-10-06 Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém

Country Status (28)

Country Link
US (1) US6703404B2 (enExample)
EP (1) EP1218378B1 (enExample)
JP (1) JP2003511450A (enExample)
KR (1) KR100793619B1 (enExample)
CN (1) CN1208336C (enExample)
AR (2) AR025959A1 (enExample)
AT (1) ATE238304T1 (enExample)
AU (2) AU7419900A (enExample)
BR (1) BR0014827A (enExample)
CA (1) CA2386804A1 (enExample)
CO (2) CO5210861A1 (enExample)
CZ (1) CZ20021241A3 (enExample)
DE (2) DE19948434A1 (enExample)
DK (1) DK1218378T3 (enExample)
ES (1) ES2198355T3 (enExample)
HK (1) HK1047749B (enExample)
HU (1) HUP0203545A3 (enExample)
IL (3) IL148997A0 (enExample)
MX (1) MXPA02003546A (enExample)
NO (1) NO20021564L (enExample)
NZ (1) NZ518438A (enExample)
PE (2) PE20010632A1 (enExample)
PL (1) PL355109A1 (enExample)
PT (1) PT1218378E (enExample)
RU (1) RU2002110281A (enExample)
SK (1) SK4622002A3 (enExample)
WO (2) WO2001027119A2 (enExample)
ZA (2) ZA200203579B (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
CN1585639A (zh) 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
US6380228B1 (en) 2000-04-10 2002-04-30 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE10043845A1 (de) * 2000-09-06 2002-03-14 Gruenenthal Gmbh Verfahren zur Messung der Aktivität der NO-Synthase
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
EP1343785A2 (de) * 2000-12-13 2003-09-17 Basf Aktiengesellschaft Verwendung von substituierten imidazoazinen, neue imidazoazine, verfahren zu deren herstellung, sowie sie enthaltende mittel
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10117184A1 (de) * 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10132726A1 (de) * 2001-07-05 2003-02-27 Gruenenthal Gmbh Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
IL164703A0 (en) 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
US20050197435A1 (en) * 2002-06-14 2005-09-08 Dotson Darin L. Polymer additive compositions for bimolecular nucleation in thermoplastics
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
DE10246890A1 (de) * 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
US7160885B2 (en) 2003-02-10 2007-01-09 Cgi Pharmaceuticals, Inc. Certain 6, 8-(heteroaryl or aryl) disubstituted imidazo[1,2-a]pyrazines as modulators of Hsp90 complex activity
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2005034949A1 (en) 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
DE102004044884A1 (de) 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
CA2581454A1 (en) 2004-09-23 2006-03-30 Reddy Us Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
PL1866296T3 (pl) 2005-04-04 2017-05-31 University Of Florida Research Foundation, Inc. Polieterowe analogi desferritiocyny
DE102005016547A1 (de) * 2005-04-08 2006-10-12 Grünenthal GmbH Substituierte 5,6,7,8-Tetrahydro-imidazo(1,2-a)pyridin-2-ylamin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
MX2007014510A (es) 2005-05-20 2008-02-05 Array Biopharma Inc Compuestos inhibidores de raf y metodos de uso de los mismos.
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
AU2006278504B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
EP1973545B1 (en) 2005-12-23 2013-01-30 Ariad Pharmaceuticals, Inc. Bicyclic heteroaryl compounds
DE102006011574A1 (de) * 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
TWI409267B (zh) 2006-03-17 2013-09-21 Ambit Biosciences Corp 治療疾病用之咪唑并噻唑化合物
CA2680592C (en) 2007-03-15 2016-07-05 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof in treating pathological conditions
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
CL2008001822A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de tiazolo[5,4-b]piridina; composicion farmaceutica que comprende a dichos compuestos; y uso del compuesto en el tratamiento de la resistencia a la insulina, sindrome metabolico, diabetes, entre otras.
TW200918542A (en) 2007-06-20 2009-05-01 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
KR101572701B1 (ko) 2007-09-19 2015-11-27 암비트 바이오사이언시즈 코포레이션 Ｎ-(5-ｔｅｒｔ-부틸-이속사졸-3-일)-Ｎ'-[4-[7-(2-모르폴린-4-일-에톡시)이미다조[2,1-Ｂ][1,3]벤조티아졸-2-일]페닐]우레아를 포함하는 고체 형태, 그의 조성물 및 그의 용도
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
ES2396126T3 (es) * 2008-04-15 2013-02-19 Eisai R&D Management Co., Ltd. Compuesto de 3-fenilpirazol[5,1-b]tiazol
WO2010032195A1 (en) 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
KR101745732B1 (ko) 2008-12-08 2017-06-12 질레드 코네티컷 인코포레이티드 이미다조피라진 ｓｙｋ 억제제
MX2011006094A (es) 2008-12-08 2011-11-29 Gilead Connecticut Inc Inhibidores de imidazopirazina syk.
CN102388054B (zh) 2008-12-19 2015-03-04 西特里斯药业公司 噻唑并吡啶沉默调节蛋白调节剂的化合物
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
BR112012022943A2 (pt) 2010-03-11 2018-06-05 Gilead Connecticut Inc inibidores de syk de imidazopiridnas
KR102111176B1 (ko) 2011-12-16 2020-05-15 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 4'-데스페리티오신 유사체의 용도
CN104540835B (zh) 2012-04-26 2017-08-08 百时美施贵宝公司 用于治疗血小板聚集的作为蛋白酶激活受体4(par4)抑制剂的咪唑并噻二唑衍生物
WO2013163241A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
TWI572605B (zh) 2012-04-26 2017-03-01 必治妥美雅史谷比公司 血小板聚集之抑制劑
BR112015010469A2 (pt) * 2012-11-14 2017-07-11 Hoffmann La Roche derivados de imidazopiridina
PT3027171T (pt) 2013-07-30 2020-06-18 Gilead Connecticut Inc Formulação de inibidores da syk
MX2016001304A (es) 2013-07-30 2016-04-07 Gilead Connecticut Inc Polimorfo de inhibidores de syk.
EP3071201A4 (en) 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
SG11201603050TA (en) 2013-12-04 2016-05-30 Gilead Sciences Inc Methods for treating cancers
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
DK3105226T3 (da) 2014-02-13 2019-10-14 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
PT3105218T (pt) 2014-02-13 2019-12-05 Incyte Corp Ciclopropilaminas como inibidores de lsd1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
MX2017000610A (es) 2014-07-14 2017-04-27 Gilead Sciences Inc Metodos combinados para tratar canceres.
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
KR20170140306A (ko) 2015-04-27 2017-12-20 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 대사적으로 프로그램화된 금속 킬레이트화제 및 그의 용도
KR102710120B1 (ko) 2015-08-12 2024-09-27 인사이트 홀딩스 코포레이션 Lsd1 저해제의 염
PE20190377A1 (es) 2016-04-22 2019-03-08 Incyte Corp Formulaciones de un inhibidor de lsd 1
WO2019014514A1 (en) * 2017-07-14 2019-01-17 University Of Massachusetts HETEROCYCLIC COMPOUNDS AND USES THEREOF
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
CA3075813A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. Small molecule inhibition of transcription factor sall4 and uses thereof
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
KR20210131372A (ko) 2019-02-22 2021-11-02 크로노스 바이오, 인코포레이티드 Syk 억제제로서의 축합된 피라진의 고체 형태
WO2024220541A1 (en) * 2023-04-18 2024-10-24 Kallyope, Inc. Nk3 modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489755A (en) * 1966-08-03 1970-01-13 Pfizer & Co C Imidazo (1,2-b) pyridazines
FR2463774A1 (fr) * 1979-08-21 1981-02-27 Yamanouchi Pharma Co Ltd Derives du 2-phenylimidazo(2,1-b)benzothiazole
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
EP0266890A1 (en) * 1986-10-07 1988-05-11 Yamanouchi Pharmaceutical Co. Ltd. Imidazopyridine derivatives, their production, and pharmaceutical compositions containing them
FR2638161B1 (fr) * 1988-10-24 1991-01-11 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
JPH08333258A (ja) * 1994-12-14 1996-12-17 Japan Tobacco Inc チアジン又はチアゼピン誘導体及びそれら化合物を含有してなる一酸化窒素合成酵素阻害剤
GB9506188D0 (en) * 1995-03-27 1995-05-17 Fujisawa Pharmaceutical Co Amidine derivatives
US5908842A (en) * 1995-12-08 1999-06-01 Merck & Co., Inc. Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase
WO1998006724A1 (en) * 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Metabotropic glutamate receptor agonists
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents

Also Published As

Publication number Publication date
ZA200203579B (en) 2003-10-29
EP1218378A2 (de) 2002-07-03
DE19948434A1 (de) 2001-06-07
HUP0203545A2 (hu) 2003-02-28
WO2001027119A2 (de) 2001-04-19
AR025959A1 (es) 2002-12-26
AU780526B2 (en) 2005-03-24
PL355109A1 (en) 2004-04-05
NO20021564D0 (no) 2002-04-03
NZ518438A (en) 2004-08-27
HK1047749B (zh) 2003-08-22
CA2386804A1 (en) 2001-04-19
IL148997A0 (en) 2002-11-10
CN1208336C (zh) 2005-06-29
AU7419900A (en) 2001-04-23
DE50001911D1 (de) 2003-05-28
CZ20021241A3 (cs) 2002-08-14
PE20010706A1 (es) 2001-08-13
JP2003511450A (ja) 2003-03-25
WO2001027119A3 (de) 2001-10-11
WO2001027109A3 (de) 2001-09-20
MXPA02003546A (es) 2002-09-18
AR025960A1 (es) 2002-12-26
WO2001027109A2 (de) 2001-04-19
DK1218378T3 (da) 2003-07-21
NO20021564L (no) 2002-06-04
KR20020069003A (ko) 2002-08-28
IL148999A0 (en) 2002-11-10
AU7915300A (en) 2001-04-23
ZA200203581B (en) 2004-02-25
US20030022914A1 (en) 2003-01-30
CN1407983A (zh) 2003-04-02
KR100793619B1 (ko) 2008-01-11
PE20010632A1 (es) 2001-07-07
RU2002110281A (ru) 2003-12-20
CO5251429A1 (es) 2003-02-28
ATE238304T1 (de) 2003-05-15
ES2198355T3 (es) 2004-02-01
US6703404B2 (en) 2004-03-09
PT1218378E (pt) 2003-09-30
HK1047749A1 (en) 2003-03-07
EP1218378B1 (de) 2003-04-23
HUP0203545A3 (en) 2004-07-28
CO5210861A1 (es) 2002-10-30
SK4622002A3 (en) 2002-09-10
IL148999A (en) 2007-03-08

Similar Documents

Publication Publication Date Title
BR0014827A (pt) Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
AU9671798A (en) Allosteric adenosine receptor modulators
BR0210838A (pt) Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com glicogênio sintase quinase-3, e de doenças, e medicação contraceptiva, e, processos para a preparação de um composto
BR0015315A (pt) Compostos, medicamentos, composições farmacêuticas, utilização de compostos e produtos industriais
BR0317283A (pt) Derivados heterocìclicos de flúor-glicosìdeo, medicamentos contendo estes compostos e seu uso
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR122019010200B8 (pt) compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BR0316605A (pt) Derivados de fluorglicosìdeos aromáticos, medicamentos contendo estes compostos e sua aplicação
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
BR0211198A (pt) Composições farmacêuticas e seu uso
ES2061799T3 (es) Nuevo preparado medicamentoso y procedimiento para su preparacion.
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BR0012610A (pt) Novo derivado de difenilpiperidina
BRPI0514310A (pt) 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
BRPI0411503A (pt) composto, composição farmacêutica, uso de um composto, método de tratar um ser humano que sofre de uma doença hiperproliferativa tal como cáncer, e, processo para a preparação de um composto
BRPI0407901A (pt) derivados de diarilcicloalquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
BR0214141A (pt) Derivados de piperidina e seu uso como moduladores da atividade de receptor de quimiocina (especialmente ccr5)
BRPI0407907A (pt) derivados de ácido alcánico substituìdos com aril-cicloaquila, processos para preparação dos mesmos e uso dos mesmos como medicamentos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.